The COVID-19 Delta variant has changed the vaccination game in Australia. With outbreaks resulting in a prolonged lockdown for Sydney as well as shorter periods for other states, the proportion of Australians vaccinated has steadily increased while vaccine hesitancy has fallen. The latest survey data collected by the Melbourne Institute…
Promising results from first-in-humans study of a novel PET radiopharmaceutical
The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and…
Two trials show promising results with gene therapies that target sickle-cell anemia
Two teams of researchers working independently have found success in trialing gene therapies targeting sickle-cell anemia. Both teams have published papers in the New England Journal of Medicine describing their work and results. The first team comprised members from the U.S., Germany, Canada and France; they used the CRISPR-Cas9 gene…
AstraZeneca’s results signal more good vaccine news—but efficacy is only the beginning of the story
AstraZeneca has become the latest pharmaceutical company to reveal promising results in clinical trials, for its viral vector vaccine developed with the University of Oxford. In a group given two full doses of the vaccine at least one month apart, the vaccine demonstrated 62% efficacy at preventing COVID. Interestingly, in…
Results from the VOYAGER PAD Trial reported
A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes…
Results from PROSPECT ABSORB reported at TCT Connect and published simultaneously in JACC
New data from PROSPECT ABSORB, a pilot randomized trial of percutaneous coronary intervention (PCI) of non-flow-limiting vulnerable plaques in native coronary arteries, found that PCI was safe, substantially enlarged follow-up lumen areas, and was associated with favorable long-term clinical outcomes. Findings were reported today at TCT Connect, the 32nd annual…
Can seniors handle results of Alzheimer’s risk tests?
(HealthDay)—As researchers hone in on ways to detect whether someone has a high risk of developing Alzheimer’s disease before they have any symptoms, mental health professionals have worried what the psychological fallout of that knowledge might be. But new research suggests that people can handle the truth. In the study,…
Oxford vaccine prompts immune response, shows promise in early results
One of the leading coronavirus vaccine candidates shows promise in early trials, triggering participants to build up immune cells against the virus without causing any severe reactions, according to results published today. The vaccine, called ChAdOx1 nCoV-19 and being developed by Oxford University in the United Kingdom, is made up…
Early research results show impacts of pandemic on children and youth
Two girls passing notes to each other through their shared backyard fence. A boy breathing a sigh of relief for not having to face unpleasant classmates at school. These are some of the stories being captured in Brock University research on the experiences of children and youth during the COVID-19…
Researchers evaluate HIV prevention intervention on farmworker communities, find positive results
Latina immigrants in farmworker communities are a vulnerable and understudied population who are at high risk for contracting HIV. Nationally, rates of new HIV infections among Latinas are more than four times that of non-Latina white women—and the rates are even higher for those in marginalized populations. Researchers from Robert…
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
NEW YORK & INDIANAPOLIS–(BUSINESS WIRE) April 18, 2019 — Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of…